CompletedPhase 2NCT03031912
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Canadian Immunization Research Network
- Principal Investigator
- Cecile Tremblay, MDCHUM
- Intervention
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine(biological)
- Enrollment
- 251 enrolled
- Eligibility
- 13-65 years · All sexes
- Timeline
- 2017 – 2023
Study locations (1)
- CHUM, Montreal, Quebec, Canada
Collaborators
Merck Sharp & Dohme LLC · International Development Research Centre, Canada · Dalhousie University · Université de Montréal · Coalition for Epidemic Preparedness Innovations · University of Ottawa · Centre Muraz · Institute for Health Research - Epidemiological Surveillance and Training (IRESSEF)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03031912 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University